Search for a trial

A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors (eNRGy)

This study has been transitioned to CTIS with ID 2024-512358-78-00 check the CTIS register for the current data. Part 1 of the trial (already completed):The primary objective of the research concerned the determination of the Maximum Tolerated Dose…